1. June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
2. Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).
3. FDA. ABECMA (idecabtagene vicleucel). https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel (2021).
4. FDA. BREYANZI (lisocabtagene maraleucel). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel (2021).
5. FDA. KYMRIAH (tisagenlecleucel). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel (2021).